Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GSK GSK	$38.26 -0.6%	$38.99	$31.72 ▼ $44.67	$78.33B	0.5	4.93 million shs	3.00 million shs
GSK GSK	$38.26 -0.6%	$38.99	$31.72 ▼ $44.67	$78.33B	0.5	4.93 million shs	3.00 million shs
IMGN ImmunoGen	$31.23	$31.23	$3.61 ▼ $31.25	$8.32B	1.18	8.78 million shs	40 shs
PFE Pfizer	$25.45 +0.5%	$23.67	$20.92 ▼ $31.54	$144.66B	0.58	41.63 million shs	27.10 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GSK GSK	-0.67%	-0.87%	-5.44%	+4.84%	-0.47%
GSK GSK	-0.67%	-0.87%	-5.44%	+4.84%	-0.47%
IMGN ImmunoGen	0.00%	0.00%	0.00%	0.00%	0.00%
PFE Pfizer	+0.49%	+4.69%	+8.89%	+10.68%	-8.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GSK GSK	2.171 of 5 stars	1.1	4.0	2.5	0.0	1.9	0.0	2.5
GSK GSK	2.171 of 5 stars	1.1	4.0	2.5	0.0	1.9	0.0	2.5
IMGN ImmunoGen	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	4.976 of 5 stars	3.2	3.0	4.2	4.5	2.8	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GSK GSK	2.10	Hold	$37.38	-2.31% Downside
GSK GSK	2.10	Hold	$37.38	-2.31% Downside
IMGN ImmunoGen	0.00	N/A	N/A	N/A
PFE Pfizer	2.45	Hold	$28.55	12.20% Upside

Current Analyst Ratings Breakdown

Latest IMGN, GSK, GSK, and PFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
6/3/2025	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/29/2025	PFE Pfizer	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$28.00 ➝ $25.00
5/21/2025	PFE Pfizer	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00
5/19/2025	PFE Pfizer	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$27.00 ➝ $26.00
4/30/2025	PFE Pfizer	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform	$22.00 ➝ $23.00
4/30/2025	PFE Pfizer	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral	$29.00 ➝ $27.00
4/30/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral	$26.00 ➝ $27.00
4/30/2025	PFE Pfizer	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Perform	$28.00 ➝ $26.00
4/30/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral	$23.00 ➝ $25.00
4/30/2025	PFE Pfizer	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral	$25.00 ➝ $27.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GSK GSK	$40.10B	1.95	$5.54 per share	6.90	$8.07 per share	4.74
GSK GSK	$40.10B	1.95	$5.54 per share	6.90	$8.07 per share	4.74
IMGN ImmunoGen	$287.61M	28.91	N/A	N/A	$0.71 per share	43.99
PFE Pfizer	$62.46B	2.32	$4.39 per share	5.80	$15.62 per share	1.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GSK GSK	$3.29B	$1.94	19.72	8.23	1.55	9.89%	48.82%	11.15%	7/30/2025 (Estimated)
GSK GSK	$3.29B	$1.94	19.72	8.23	1.55	9.89%	48.82%	11.15%	7/30/2025 (Estimated)
IMGN ImmunoGen	-$222.93M	-$0.31	N/A	84.41	N/A	-25.56%	-22.11%	-13.53%	N/A
PFE Pfizer	$8.03B	$1.38	18.44	8.40	0.92	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest IMGN, GSK, GSK, and PFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	GSK GSK	$1.12	N/A	N/A	N/A	$7.92 billion	N/A
7/30/2025	Q2 2025	GSK GSK	$1.12	N/A	N/A	N/A	$7.92 billion	N/A
4/30/2025	Q1 2025	GSK GSK	$1.08	$1.13	+$0.05	$1.00	$7.52 billion	$10.06 billion
4/30/2025	Q1 2025	GSK GSK	$1.08	$1.13	+$0.05	$1.00	$7.52 billion	$10.06 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GSK GSK	$1.69	4.42%	N/A	87.11%	N/A
GSK GSK	$1.69	4.42%	N/A	87.11%	N/A
IMGN ImmunoGen	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.76%	N/A	124.64%	16 Years

Latest IMGN, GSK, GSK, and PFE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
5/2/2025	GSK GSK	quarterly	$0.4216	4.1%	5/16/2025	5/16/2025	7/10/2025
5/2/2025	GSK GSK	quarterly	$0.4216	4.1%	5/16/2025	5/16/2025	7/10/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GSK GSK	1.21	0.87	0.58
GSK GSK	1.21	0.87	0.58
IMGN ImmunoGen	0.13	5.70	5.65
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GSK GSK	15.74%
GSK GSK	15.74%
IMGN ImmunoGen	90.50%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
GSK GSK	10.00%
GSK GSK	10.00%
IMGN ImmunoGen	5.07%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GSK GSK	68,629	2.05 billion	1.84 billion	Optionable
GSK GSK	68,629	2.05 billion	1.84 billion	Optionable
IMGN ImmunoGen	277	266.26 million	252.76 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

IMGN, GSK, GSK, and PFE Headlines

Recent News About These Companies

Pfizer’s Elranatamab Study: Key Insights for Investors

4 hours ago | tipranks.com

Pfizer’s Promising Study on Elranatamab for Multiple Myeloma

4 hours ago | tipranks.com

Pfizer’s New Cancer Treatment Study: A Potential Game-Changer for Advanced Solid Tumors

4 hours ago | tipranks.com

Pfizer’s Elranatamab Study: A New Hope for Multiple Myeloma Patients

4 hours ago | tipranks.com

Pfizer’s ABRYSVO Vaccine Study: A Potential Game-Changer for RSV Prevention

4 hours ago | tipranks.com

Pfizer’s Phase 3 RSV Vaccine Study: A Potential Game-Changer for Pregnant Women

4 hours ago | tipranks.com

Pfizer’s Promising Phase 3 Study on Elranatamab for Multiple Myeloma

4 hours ago | tipranks.com

Pfizer’s Promising Trial for Relapsed Refractory Multiple Myeloma

4 hours ago | tipranks.com $https://www.tipranks.com/news/company-announcements/pfizers-promising-trial-for-relapsed-refractory-multiple-myeloma?utm_source=marketbeat.com&utm_medium=referral$

Pfizer’s MagnetisMM-32 Study: A New Hope for Multiple Myeloma Treatment?

4 hours ago | tipranks.com

Pfizer’s New Phase 3 Trial: A Potential Game-Changer in Prostate Cancer Treatment?

4 hours ago | tipranks.com

Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025)

July 4 at 9:36 AM | 247wallst.com

Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025)

July 4 at 9:00 AM | 247wallst.com

Kintegral Advisory LLC Sells 57,229 Shares of Pfizer Inc. (NYSE:PFE)

July 4 at 8:38 AM | marketbeat.com

IFM Investors Pty Ltd Has $29.86 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

July 4 at 8:04 AM | marketbeat.com

Avantax Planning Partners Inc. Grows Position in Pfizer Inc. (NYSE:PFE)

July 4 at 7:27 AM | marketbeat.com

Calamos Wealth Management LLC Buys 12,647 Shares of Pfizer Inc. (NYSE:PFE)

July 4 at 7:18 AM | marketbeat.com

Cohen Investment Advisors LLC Purchases 10,097 Shares of Pfizer Inc. (NYSE:PFE)

July 4 at 7:17 AM | marketbeat.com

Calamos Advisors LLC Has $45.01 Million Position in Pfizer Inc. (NYSE:PFE)

July 4 at 7:03 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Sold by Aviance Capital Partners LLC

July 4 at 7:02 AM | marketbeat.com

Aurora Private Wealth Inc. Takes $986,000 Position in Pfizer Inc. (NYSE:PFE)

July 4 at 6:35 AM | marketbeat.com

Principal Financial Group Inc. Decreases Holdings in Pfizer Inc. (NYSE:PFE)

July 4 at 5:56 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMGN, GSK, GSK, and PFE Company Descriptions

GSK NYSE:GSK

$38.26 -0.25 (-0.65%)

Closing price 07/3/2025 03:52 PM Eastern

Extended Trading

$38.28 +0.02 (+0.04%)

As of 07/3/2025 04:59 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GSK NYSE:GSK

$38.26 -0.25 (-0.65%)

Closing price 07/3/2025 03:52 PM Eastern

Extended Trading

$38.28 +0.02 (+0.04%)

As of 07/3/2025 04:59 PM Eastern

ImmunoGen NASDAQ:IMGN

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Pfizer NYSE:PFE

$25.44 +0.13 (+0.49%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$25.42 -0.03 (-0.11%)

As of 07/3/2025 05:00 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time